AEE788 is primarily utilized in research and development within the field of oncology. It serves as a potent inhibitor targeting multiple tyrosine kinases, including EGFR (Epidermal Growth Factor Receptor), VEGFR (Vascular Endothelial Growth Factor Receptor), and HER2/neu. This makes it a valuable tool in studying cancer cell signaling pathways and tumor angiogenesis. Researchers employ AEE788 to investigate its effects on inhibiting tumor growth and proliferation, particularly in cancers driven by these receptors. Additionally, it is used in preclinical studies to explore combination therapies and resistance mechanisms, aiding in the development of novel cancer treatments. Its application extends to understanding the molecular basis of tyrosine kinase-related diseases, providing insights for therapeutic interventions.